Bend Research Highlights Cutting-Edge Technologies At AAPS Annual Meeting and Exposition

October 9, 2012

Bend, Ore. – Bend Research Inc., a leading independent scientific development and manufacturing company, has announced a full schedule of events at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition Oct. 14 through 18 at McCormick Place in Chicago, Ill.

"We are excited to be attending our seventh AAPS Annual Meeting and Exposition," said "Rod Ray, chairman and CEO of Bend Research. "During the last year, we have continued to focus on developing cutting-edge drug-delivery technologies and solving our clients’ most challenging drug delivery problems. We look forward to sharing our research, and meeting with clients and peers to collaborate on common challenges facing the pharmaceutical industry."

Bend Research will participate in a number of technical events during the conference.

Dwayen Friesen, Ph.D., will present at the Workshop on Oral Bioperformance and 21st Century Testing October 13-14.

On Oct. 16, David Vodak, Ph.D., will present during a symposium titled, "Predicting In Vivo Oral Drug Absorption using Biorelevant In Vitro Testing: Current Approaches and Future Directions."

Also, on Oct. 16 is the "Innovation in the 21st Century: Large Pharma and Small Drug Delivery Company Collaborations" roundtable, featuring David Lyon, Ph.D. Additionally, Lyon will lead a symposium titled "New Excipients: Unmet Needs, Development and Regulator Challenges" on Oct. 18.

Bed Research scientists will present five posters during the meeting:

-- "Pharmacokinetic and Stability Analysis of an Inhalable Formulation of Nanocrystalline Campotothecin for the Treatment of Lung Cancer," presented by Jeff Breit, Ph.D.

-- "Prediction of Crystallization Kinetics for a Spray-Dried Dispersion Using Isothermal Calorimetry," presented by David Vodak, Ph.D.

-- "Tabletability of Hydroxypropylmethlcellulose Acetate Succinate (HPMCAS) Spray-Dried Dispersions (SDDs)," presented by Randy Wald, R.Ph.

-- "Modullation of Dissolution Rate and Pharmacokinetics for a High-Energy Nanocrystalline Form of Ziprasidone," presented by Chris Craig, Ph.D.

-- "Hypromellose Acetate (HPMCA): Synthesis, Characterization and In Vitro/In Vivo Performance of a Novel Excipient for the Solubilization of Low-Solubility Acid-Labile Drugs," presented by Rod Ketner, Ph.D.

Bend Research will be at Booth 5017 throughout the exposition and will host a cocktail hour there on Oct. 15 and 16. Cocktail hour attendees will have the opportunity to participate in a drawing for a Nike FuelBand.

Editor's Note: To schedule an interview with Bend Research experts or any other press inquiry, please contact Phoenix Barringer at phoenix.barringer@bendresearch.com or 541-382-4100, or via cell phone at 541-678-8365.

###

About Bend Research Inc.

For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.

Bend Research provides a wide range of capabilities, including formulation and dosage-form support; assists in process development and optimization; manufactures clinical-trial quantities of drug candidates in its cGMP facilities; and advances promising drug candidates from conception through commercialization. Bend Research is a leader in novel formulations, including SDDs and hot-melt extrusions, and controlled-release, inhalation, and biotherapeutics technologies.

Bend Research has more than 300 employees based in six state-of-the-art faciltiies in Bend, Ore., USA.